Molecular Hydrogen Capsule Therapy for Primary Biliary Cholangitis With Elevated IgG4: A Case Report on Immune Marker...

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Background:

• Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease.
• Ursodeoxycholic acid (UDCA) is the standard treatment, but some patients have poor responses.
• Molecular hydrogen (H2) possesses antioxidant and anti-inflammatory properties beneficial for autoimmune conditions.

Purpose of the Study:

• To evaluate the efficacy of H2 capsules as an adjunctive therapy for PBC.
• To assess the impact of H2 on liver enzymes and immune dysregulation in PBC patients.
• To explore H2's potential in improving quality of life for PBC patients.

Main Methods:

• A case report of a 44-year-old male with PBC and elevated liver enzymes was studied.
• H2 capsule therapy was administered as an adjunct to UDCA treatment.
• Liver enzymes, immune markers, and clinical symptoms were monitored over four months.

Main Results:

• Significant reductions in AST and ALT levels were observed after H2 therapy.
• Immune markers (KLRG-1, PD-1, Tim3) normalized, and IgG4 levels decreased.
• Patient reported improvements in fatigue and pruritus, with stable fibrosis on imaging.

Conclusions:

• H2 capsules may be a safe and effective adjunctive treatment for PBC.
• H2 therapy can improve liver enzyme levels, immune regulation, and patient well-being.
• Further research is needed to establish H2 protocols for autoimmune liver diseases.